Abstract
New RSV vaccines and mAbs in late-stage trials show promising clinical effectiveness, however evidence of economic value and affordability must also be considered if these interventions are to be accessible in LMICs where the burden is greatest. This systematic review’s objective was to summarise existing evidence on cost-of-illness and cost-effectiveness of RSV prevention interventions for children in LMICs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
